ZUG, Switzerland and NEW YORK, Nov. 30, 2015 /PRNewswire/ -- SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company focused on innovative products to treat cancers and central nervous system (CNS) diseases, today announced that positive data from the Company's clinical studies of its WT1 cancer vaccine in patients with malignant pleural mesothelioma (MPM) and acute myeloid leukemia (AML) were reported at the International WT1 Conference, held in Kyoto, Japan, earlier this month. Clinically meaningful prolonged survival was demonstrated in both patient groups. A median overall survival of 52.5 months was achieved in a Phase 2 trial of the WT1 vaccine in adult patients with AML. Similarly, in a previous Phase 1 AML study, the WT1 vaccine resulted in a median overall survival of more than 5 years. When combined, the results from the Phase 1 and Phase 2 studies demonstrated a 2-year overall survival in adult AML patients of 79%. Historical 2-year overall survival results in similar patient populations range from 30% to 45%.
Additionally, a randomized, double-blind, placebo-controlled Phase 2 study in MPM patients at Memorial Sloan Kettering Cancer Center and M.D. Anderson Cancer Center showed a median overall survival of 21.4 months for WT1 vaccine-treated patients versus 16.6 months overall survival for patients in the placebo control arm at a recently updated review. The WT1 cancer vaccine also resulted in a median progression-free survival of 11.4 months, double that of the control arm, 5.7 months, in patients with MPM. In both the AML and MPM trials, SELLAS's WT1 vaccine demonstrated a favorable safety and tolerability profile. These and other clinical data were reported at the International WT1 Conference in an oral presentation, titled "Clinical Development of a Multivalent WT1 Peptide Vaccine for Leukemias and Solid Tumors," delivered by David A. Scheinberg, M.D., Ph.D., an inventor of the WT1 vaccine and Chairman of the Molecular Pharmacology Program and of the Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center (MSK).
Read more: http://www.prnewswire.com/news-releases/sellas-life-sciences-reports-positive-wt1-cancer-vaccine-clinical-results-in-mesothelioma-and-acute-myeloid-leukemia-aml-patients-at-the-annual-international-wt1-conference-300185027.html